Hepion Pharmaceuticals Further more Strengthens Board with Appointments of Completed Biopharmaceutical Executives, Mr. Anand Reddi and Dr. Kaouthar Lbiati
EDISON, N.J., June 28, 2022 (World NEWSWIRE) — Hepion Prescription drugs, Inc. (NASDAQ:HEPA), a medical mid-stage biopharmaceutical enterprise focused on Synthetic Intelligence (“AI”)-driven therapeutic drug improvement for the cure of non-alcoholic steatohepatitis (“NASH”) and hepatocellular carcinoma (“HCC”), nowadays introduced the appointments of Anand Reddi, M.S., and Kaouthar Lbiati, M.D., to its Board of Directors, effective promptly.
“We are thrilled to welcome persons of this caliber to our Board,” stated Hepion’s Chairman, Gary S. Jacob, Ph.D. “Mr. Reddi and Dr. Lbiati have a amazing prosperity of experience throughout all areas of drug development, from medical investigation to medical affairs, promoting, current market accessibility and client advocacy. Their blended expertise arrives at an opportune time, as we are in closing preparations to progress our lead drug applicant, rencofilstat, into 3 Period 2 clinical trials, and are starting to actively discover partnering and licensing prospects for this liver-concentrating on, orally administered, novel cyclophilin inhibitor.”
Appointment of Anand Reddi
Mr. Reddi has an achieved background, spanning a assortment of actions such as corporate strategy, strategic partnerships, R&D method, trader relations, company affairs, medical affairs, international business functions, world internet marketing, industry obtain and affected individual advocacy during his time in the international biopharmaceutical marketplace. He is currently Vice President of Company System and Exterior Affairs & Engagement, as perfectly as Chief of Staff at Adverum Biotechnologies, a medical-stage gene therapy firm concentrating on unmet clinical demands in ocular and uncommon ailments. Prior to becoming a member of Adverum, Mr. Reddi held strategic and operational leadership positions of rising accountability during his seven-yr profession at Gilead Sciences, most not long ago serving as Director and Head, Digital Innovation Buyer Engagement. At Gilead, Mr. Reddi was instrumental in establishing international access and emerging markets initiatives in above 140 nations around the world for the HIV medications Truvada®, Descovy®, Genvoya® and Biktarvy® hepatitis B treatments Viread® and Vemlidy® and the hepatitis C cures Sovaldi®, Harvoni®, Epclusa® and Vosevi® resulting in about 20 million individuals with entry to these treatment plans in source constrained settings. Formerly, he was active in HIV/AIDS international health and fitness policy, basic science and medical study targeted on bone tissue engineering, and skin cancer metastasis and signal transduction.
Mr. Reddi has authored or co-authored more than 20 peer-reviewed articles or blog posts in scientific journals these types of as Science, Character Biotechnology, JAMA Pediatrics, and AIDS published op-eds for quite a few major media stores, these as The Washington Publish and The New York Moments and is a highlighted blogger on The Huffington Post. He holds a Learn of Science diploma from the College of Colorado School of Medication, in which he studied medicine. He been given a Bachelor of Arts diploma in history and a Bachelor of Science degree in biology from the University of Michigan. In addition, Mr. Reddi has the distinction of serving as a J. William Fulbright Scholar in South Africa.
Mr. Reddi commented, “I am honored to be part of the Hepion Board significantly as the Company is at the stage the place its clinical software is maturing, and its things to do are progressively encompassing all those locations of fascination I feel I will be ready to most effect. What excites me most about Hepion is the good potential of the Company’s guide drug to benefit the thousands and thousands of folks struggling from long-term liver disorder, which include NASH and HCC. I believe my comprehensive encounter in biopharma strategy and operations, as very well as dealing with world general public health problems, will make an influence as we move ahead with the progress of rencofilstat as a prospective transformational drugs and carry value to individuals, medical professionals, and health treatment systems.”
Appointment of Dr. Kaouthar Lbiati
Dr. Lbiati is a multi-useful govt with a mixture of scientific, business, finance, international health coverage, and overall health economics competencies. She is at this time Vice President, Technique & Company Progress at Cytovia Therapeutics, a biopharmaceutical company specializing in immuno-oncology and cell therapies. Dr. Lbiati formerly served in global and regional management roles at Amgen, Glaxo Smith Kline, and Sanofi, where by she supported the registration, launch and/or sign extension and reimbursement of three ground breaking most cancers drugs – Blincyto®, Jevtana® and Votrient® – in the U.S., EU and MENA areas, with a emphasis on world clinical affairs strategic arranging, wellbeing economics and results study and market accessibility across several international locations. Most not long ago, Dr. Lbiati has served as a strategic advisor to a number of biotech providers and venture funds corporations. She headed the portfolio technique at Steba Biotech (a radio-pharmaceutical and oncology enterprise) served as a professional medical technological know-how financial investment marketing consultant to Forepont Funds Companions and was Director, Strategic Market Access at Amaris, a worldwide pharmaceutical consulting enterprise.
Dr. Lbiati obtained a Health practitioner of Medicine diploma from Rabat, Morocco’s Mohammed V College, a fellowship in oncology from the Gustave Roussy Institute in Paris, a Specialized Government Master’s degree in Strategy & Administration from ESSEC Small business Faculty in Paris, and a Master of Science in Intercontinental Plan and Overall health Economics from the London Faculty of Economics.
“I am happy to be joining the Hepion Board at this momentous time, as I imagine Hepion’s rencofilstat has the opportunity to grow to be an significant new procedure for NASH and HCC, and the Company is in the midst of planning this promising applicant for Period 2 trials in equally indications,” commented Dr. Lbiati. “One of the important factors as the Company moves forward with further more scientific growth of rencofilstat will contain strategic issues that have been a eager desire of mine during my job. I glimpse ahead to contributing to the function of the Board and Hepion’s pioneering administration group as we go on to progress rencofilstat’s progress application.”
About Hepion Prescription drugs
The Firm’s lead drug prospect, rencofilstat, is a potent inhibitor of cyclophilins which are involved in a lot of sickness processes. Rencofilstat is presently in scientific-section progress for the remedy of NASH, with the possible to impact the general training course of illness at numerous phases, from triggering occasions as a result of to conclude-phase condition. Rencofilstat has been proven to reduce liver fibrosis and hepatocellular carcinoma tumor load in experimental types of NASH, and has shown antiviral pursuits to HBV, HCV, and HDV through a number of mechanisms in nonclinical research. In November 2021, the U.S. Foods and Drug Administration (“FDA”) granted Fast Observe designation for rencofilstat for the treatment of NASH. That was soon followed in December 2021 by the FDA’s acceptance of Hepion’s investigational new drug (IND) application for rencofilstat for the treatment of hepatocellular carcinoma (HCC). In June 2022, rencofilstat was granted Orphan Drug designation by the Food and drug administration for the remedy of HCC.
Hepion has produced a proprietary AI platform, called AI-POWR™, which stands for Artificial Intelligence – Precision Medicine Omics (which include genomics, proteomics, metabolomics, transcriptomics, and lipidomics) World databases accessibility and Response and medical results. Hepion intends to use AI-POWR™ to help discover which NASH individuals will greatest reply to rencofilstat, perhaps shortening development timelines and increasing the delta concerning placebo and therapy groups. In addition to using AI-POWR™ to drive its ongoing NASH clinical development program, Hepion intends to use the platform to determine further prospective indications for rencofilstat to broaden the company’s footprint in the cyclophilin inhibition therapeutic place.
Sure statements in this push launch are ahead-on the lookout inside the which means of the Non-public Securities Litigation Reform Act of 1995. These statements may well be determined by the use of forward-seeking terms such as “anticipate,” “believe,” “forecast,” “estimated,” and “intend,” among the some others. These forward-looking statements are dependent on Hepion Pharmaceuticals’ existing anticipations and true final results could vary materially. There are a range of elements that could trigger true situations to differ materially from those people indicated by these kinds of ahead-seeking statements. These aspects contain, but are not constrained to, considerable competitors our capability to carry on as a likely concern our will need for added financing uncertainties of patent defense and litigation dangers associated with delays, increased expenses and funding shortages brought on by the COVID-19 pandemic uncertainties with respect to lengthy and highly-priced medical trials, that benefits of earlier research and trials may not be predictive of long term demo results uncertainties of govt or 3rd party payer reimbursement minimal revenue and marketing attempts and dependence upon third events and threats similar to failure to obtain Fda clearances or approvals and noncompliance with Food and drug administration regulations. As with any drug candidates underneath improvement, there are sizeable pitfalls in the enhancement, regulatory approval, and commercialization of new goods. There are no guarantees that upcoming clinical trials reviewed in this press release will be completed or thriving, or that any solution will get regulatory acceptance for any indicator or prove to be commercially thriving. Hepion Prescribed drugs does not undertake an obligation to update or revise any forward-looking assertion. Investors must go through the danger things set forth in Hepion Pharmaceuticals’ Sort 10-K for the calendar year ended December 31, 2021, and other periodic experiences submitted with the Securities and Trade Commission.
For even further information, remember to call:
Hepion Prescription drugs Trader Relations
Direct: (646) 274-3580